Publications

5808 Results

A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): A Gynecologic Oncology Group, SWOG, NCCTG and ECOG study.

Authors
GA Omura;MF Brady;JE Delmore;HJ Long;KY Look;HE Averette;S Wadler;G Spiegel
Journal / Conference
American Society of Clinical Oncology 15:280(#755)
Year
1996
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-9238 (INT-0134) (GOG-134) (NCCTG-92-61-51)

A phase II trial of paclitaxel in patients with metastatic refractory carcinoma of the breast: A Southwest Oncology Group (SWOG) study.

Authors
CE Geyer Jr;SJ Green;C Moinpour;J O'Sullivan;D Goodwin;V Canfield;V Hamaski;S Martino
Journal / Conference
American Society of Clinical Oncology 15:107(#92)
Year
1996
Research Committee(s)
Breast
Study Number(s)
SWOG-9248

bcl-2, p53, and response to tamoxifen in er-positive metastatic breast cancer.

Authors
R Elledge;S Green;L Howes;M Berardo;DC Allred;D Ciocca;CK Osborne;P Ravdin;J O'Sullivan;G Langone
Journal / Conference
American Society of Clinical Oncology 15:123(#159)
Year
1996
Research Committee(s)
Breast
Study Number(s)
SWOG-9314

Gender differences and independent predictors of survival in patients with metastatic malignant melanoma on SWOG trials.

Authors
L Flaherty;J Unger;PY Liu;K Albain;V Sondak
Journal / Conference
American Society of Clinical Oncology 15:433(#1344)
Year
1996
Research Committee(s)
Melanoma

Metastatic breast cancer (MBC) in complete remission (CR): Observation versus CMFPTH maintenance: An ECOG randomized study.

Authors
G Falkson;RC Gelman;KJ Pandya;CK Osborne;GW Sledge;MD Abeloff
Journal / Conference
American Society of Clinical Oncology 15:99(#63)
Year
1996
Research Committee(s)
Breast

Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and roferon-A: A Southwest Oncology Group study.

Authors
ME Marshall;M Wolf;M O'Rourke;TC Barnett;ED Crawford
Journal / Conference
Cancer Biotherapy & Radiopharmaceuticals 11(2):119-123
Year
1996
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8955

Clinical behavior of 2,168 patients treated on Southwest Oncology Group (SWOG) protocols and reclassified according to the REAL classification.

Authors
RI Fisher;TM Grogan;S Dahlberg;R Braziel;P Banks;B Nathwani;C Kjeldsberg;TP Miller
Journal / Conference
Annals of Oncology 7(Suppl.3):3(#006)
Year
1996
Research Committee(s)
Lymphoma

REAL classification of lymphoma allows improved delineation of histologic risk groups: A Southwest Oncology Group (SWOG) study.

Authors
TM Grogan;TP Miller;S Dahlberg;R Braziel;P Banks;B Nathwani;C Kjeldsberg;R Tubbs;RI Fisher
Journal / Conference
American Society of Clinical Oncology 15:425(1310)
Year
1996
Research Committee(s)
Lymphoma

Cytogenetics, MDR1, and disease status in elderly AML identify a subgroup with a high complete remission (CR) rate: A Southwest Oncology Group study.

Authors
ML Slovak;KJ Kopecky;T McConnell;CP Leith;J Godwin;IM Chen;C Rankin;DR Head;F Appelbaum;CL Willman
Journal / Conference
British Journal of Haematology 93(Suppl.2):134(#522)
Year
1996
Research Committee(s)
Leukemia
Study Number(s)
SWOG-9031

Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): Report of a Southwest Oncology Group study (SWOG-9308).

Authors
AJ Wozniak;JJ Crowley;SP Balcerzak;GR Weiss;LR Laufman;LH Baker;RI Fisher;SI Bearman;SA Taylor;RB Livingston
Journal / Conference
American Society of Clinical Oncology 15:374(#111)
Year
1996
Research Committee(s)
Lung
Study Number(s)
SWOG-9308